Fund priority antibacterial products through milestone-based public and nonprofit programmes
#00392
Provide grants and milestone payments for high-priority antibiotics, diagnostics and nontraditional products while attaching stewardship, access and data-sharing conditions.
Parent issue
#00372 The antibiotic development and commercialization system fails to deliver needed treatments
Sustainable Development Goals
Location
Description
Governments, foundations and product-development partnerships should fund discovery, preclinical work and clinical development against clearly defined priority pathogens and target product profiles. Payments should be tied to technical milestones, independent review and transparent portfolio decisions.
Funding agreements should include affordable access, responsible manufacturing, stewardship, publication of results and continuity plans if a developer fails. Push funding reduces early scientific risk but does not by itself solve post-approval revenue or global delivery.
Sub-issues
0Case studies
0